Is Hormonal Treatment of Congenital Undescended Testes Justified? A Debate

Sex Dev. 2019;13(1):3-10. doi: 10.1159/000496418. Epub 2019 Jan 26.

Abstract

Abnormal germ cell development in cryptorchidism is not a result of a congenital dysgenesis but is preceded by a hormone imbalance and perturbation in germ cell-specific gene expression during abrogated mini-puberty. Adequate treatment with low doses of GnRHa enables 86% of men to achieve a normal sperm count and, most importantly, prevent development of azoospermia. GnRHa treatment induces a significant transcriptional response, including protein coding genes involved in pituitary development, the hypothalamic-pituitary-gonadal axis, and testosterone synthesis. Furthermore, hormonal treatment to achieve epididymo-testicular descent as a first choice of treatment of cryptorchidism has a long tradition in Europe. It eliminates the necessity of subsequent surgery. Moreover, in the cases of non-responders it facilitates orchidopexy and contributes considerably to a reduced incidence of unilateral and the more serious bilateral complete post-surgical testicular atrophy.

Keywords: Cryptorchidism; Hormonal treatment; Mini-puperty; Orchidopexy.

Publication types

  • Review

MeSH terms

  • Cryptorchidism / drug therapy*
  • Cryptorchidism / genetics
  • Cryptorchidism / pathology
  • Cryptorchidism / surgery
  • DNA Transposable Elements / genetics
  • Hormones / therapeutic use*
  • Humans
  • Infertility, Male / therapy
  • Male
  • RNA / genetics
  • RNA / metabolism
  • Sperm Count

Substances

  • DNA Transposable Elements
  • Hormones
  • RNA